Ocular drug delivery in veterinary medicine

Advanced Drug Delivery Reviews

Volumn 28, Issue 3, 1997, Pages 335-361

  Baeyens, Vincent ^a   Percicot, Christine ^b   Zignani, Monia ^a   Deshpande, Arati A ^a   Kaltsatos, Vassilios ^c   Gurny, Robert ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b CIBA GEIGY LTD   (Switzerland)

^c Vétoquinol Magny Vernois ^*  (France)

Author keywords

Eye; Ocular drug delivery; Veterinary

Indexed keywords

DRUG PRODUCTS; OPHTHALMOLOGY; PHYSIOLOGY;

ANATOMY; OCULAR DRUG DELIVERY; PATHOLOGY; VETERINARY MEDICINE;

CONTROLLED DRUG DELIVERY;

AGENTS ACTING ON THE EYE; ANTIBIOTIC AGENT; ARTIFICIAL TEAR; ATROPINE; CHITOSAN; CHOLINESTERASE INHIBITOR; COLLAGEN; CYCLOSPORIN; DEXAMETHASONE SODIUM PHOSPHATE; DICLOFENAC; ETHYLMORPHINE; EYE DROPS; FLURBIPROFEN; GELLAN; GENTAMICIN; GLUCOCORTICOID; GROWTH FACTOR; HYALURONIC ACID; IDOXURIDINE; INDOMETACIN; KETOROLAC; NONSTEROID ANTIINFLAMMATORY AGENT; PILOCARPINE; PREDNISOLONE; PRODRUG; RETINOL; SALICYLIC ACID; SUPROFEN; UNINDEXED DRUG; VIDARABINE;

CORNEA ULCER; DRUG ADMINISTRATION; DRUG DELIVERY SYSTEM; EYE DISEASE; EYE INFECTION; EYE INFLAMMATION; GLAUCOMA; HYDROGEL; INTRAVITREAL DRUG ADMINISTRATION; IONTOPHORESIS; KERATOCONJUNCTIVITIS; NONHUMAN; OINTMENT; PRIORITY JOURNAL; REVIEW;

EID: 0031560444     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(97)00088-4     Document Type: Review

References (253)

1. K.N. Gelatt, Ophthalmologits need to focus on extra-label drug use initiative. Letter to the Editor, J. Am. Vet. Med. Assoc. 203 (1993) 497.
2. H.E. Evans, G.C. Christensen, Miller's Anatomy of the Dog, 2nd ed. WB Saunders, Philadelphia, 1979.
3. J.H. Prince, C.D. Diesem, I. Eglitis, G. Ruskell, in: Charles C. Thomas (Ed.), Anatomy and Histology of the Eye and Orbit in Domestic Animals. Springfield, IL, 1960.
4. M.V. Riley, K. Green, Comparative physiology and biochemistry of the eye, in: Hockwin, Green, Rubin (Eds.), Manual of Oculotoxicity Testing of Drugs, Gustav Fisher Verlag, 1992, pp. 45-80.
5. J.V. Schoster, L. Wickman, C. Stuhr, The use of ultrasonic pachymetry and computer enhancement to illustrate the collective thickness profile of 25 cats, Vet. Comp. Ophthalmol. 5 (1995) 68.
6. C.J. Murphy, T.J. Kern, H.C. Rowland, Refractive state, corneal curvature, accommodative range and ocular anatomy of the Asian elephant (Elephas maximus), Vis. Res. 32 (1992) 2013-2021.
7. K.P. Barrie, G.G. Gum, D.A. Samuelson, K.N. Gelatt, Morphologic studies of uveoscleral outflow in normotensive and glaucomatous beagles with fluorescein-labeled dextran, Am. J. Vet. Res. 46 (1985) 89-97.
8. A. Bill, The route for bulk drainage of aqueous humor in rabbits with and without cyclodialysis, Doc. Ophthalmol. 20 (1966) 157-169.
9. A. Bill, C.I. Phillips, Uveoscleral drainage of aqueous humor in human eyes, Exp. Eye Res. 12 (1971) 275-281.
10. P.G.C. Bedford, I. Grierson, Aqueous drainage in the dog, Res. Vet. Sci. 41 (1986) 172-186.
11. A. Bill, Aqueous humor dynamics in monkeys (Macaca, irus and Cercopithecus ethiops), Exp. Eye Res. 11 (1971) 195-206.
12. P. Smith, D. Samuelson, D. Brook, Aqueous drainage paths in the equine eye: Scanning electron microscopy of corrosion casts, J. Morphol. 198 (1998) 33-42.
13. D. Samuelson, P. Smith, D. Brooks, Morphologic features of the aqueous humor drainage pathways in horses, Am. J. Vet. Res. 50 (1989) 720-727.
14. K.N. Gelatt, Veterinary Ophthalmology. Lea and Febiger, Philidelphia, PA, 2nd edn., 1991.
15. G.A. Severin, Veterinary Ophthalmology Notes. Fort Collins, CO, 2nd edn., 1976.
16. D. Slatter, Fundamentals of Veterinary Ophthalmology. WB Saunders, 2nd edn., 1990.
17. N. Hakanson, S.D. Forrester, Uveitis in the dog and cat, Vet. Clin. North Am. Small Anim. Pract. 20 (1990) 715-735.
18. S.M.P. Jones, P.G.C. Bedford, Ocular antimicrobial therapy in small animal practice, J. Small Anim. Pract. 30 (1989) 550-578.
19. N.J. Millichamp, J. Dziezyc, Comparison of fluxinin meglumine and flurbiprofen for control irritative response in dogs, Am. J. Vet. Res. 52 (1991) 1452-1455.
20. P.R. Badenoch, G.J. Hay, P.J. McDonald, D.J. Coster, A rat model of bacterial keratitis - effect of antibiotics and corticosteroid, Arch. Ophthalmol. 103 (1985) 718-722.
21. G.L. Zhan, O.C. Miranda, L.Z. Bito, Steroid glaucoma: corticosteroid-induced ocular hypertension in cats, Exp. Eye. Res. 54 (1992) 211-218.
22. P Lees, S.A. May, Q.A. McKellar, Pharmacology and therapeutics of non-steroidal antiinflammatory drugs in the dog and cat: 1 General pharmacology, J. Small Anim. Pract. 32 (1991) 183-193.
23. C.G. MacAllister, S.J. Morgan, A.T. Borne, R.A. Pollet, Comparison of adverse effects of phenylbutazone, fluxinin meglumine, and ketoprofen in horses, J. Am. Vet. Med. Assoc. 202 (1993) 71-77.
24. Q.A. McKellar, S.A. May, P Lees, Pharmacology and therapeutics of non-steroidal antiinflammatory drugs in the dog and cat: 2 individual agents, J. Small Anim. Pract. 32 (1991) 225-235.
25. A.M. Regnier, O. Dossin, E.E. Cutzach, Comparative effects of two formulations of indomethacin eyedrops on the paracentesis-induced inflammatory response of the canine eye, Vet. Compar. Ophthalmol. 5 (1995) 242-246.
26. N.L. Verbey, J.L. Van Delft, N.J. Van Haeringen, P Braquet, Platelet-activating factor and laser trauma of the iris, Invest. Ophthalmol. Vis. Sci. 30 (1989) 1101-1103.
27. G.C.Y. Chiou, Q. Yao, M.S. Chang, T. Okawara, Prevention and treatment of ocular inflammation with a new class of non-steroidal antiinflammatory agents, J. Ocular Pharm. 10 (1994) 335-347.
28. J. Dziezyc, N.J. Millichamp, B.H. Rohde, J.S. Baker, G.C. Chiou, Effects of lipoxygenase inhibitors in a model of lens-induced uveitis in dogs, Am. J. Vet. Res. 50 (1989) 1877-1882.
29. J. Dziezyc, N.J. Millichamp, B.H. Rohde, W.B. Smith, Comparison of prednisolone and RMI-1068 in the ocular irritative response in dogs, Invest. Ophthalmol. Vis. Sci. 33 (1992) 460-465.
30. K.C. Barnett, J. Sansom, Diagnosis and treatment of keratoconjunctivitis sicca in the dog, Vet. Rec. 120 (1987) 340-345.
31. D.L. Berger, R.H. Scagliotto, E.M. Lund, A quantitative study of the effects of tribissen on canine tear production, J. Am. Anim. Hosp. Assoc. 32 (1995) 236-241.
32. G.D. Aguirre, Keratoconjunctivitis sicca in dogs, J. Am. Vet. Med. Assoc. 158 (1971) 1566.
33. R.L. Kaswan, M.A. Salisbury, C.D. Lothrup, Interaction of age and gender on occurrence of canine keratoconjunctivitis sicca, Prog. Vet. Comp. Ophthalmol. 1 (1991) 93-97.
34. G.M. Bryan, D.H. Slatter, Keratoconjunctivitis sicca induced by phenazopyridine in dogs, Arch. Ophthalmol. 90 (1973) 310.
35. L.F. Rubin, G. Aguirre, Clinical use of pilocarpine for keratoconjunctivitis sicca in dogs and cats, J. Am. Vet. Med. Assoc. 151 (1967) 313-320.
36. E.M. Smith, N.C. Buyukmihci, T.B. Farver, Effect of topical pilocarpine treatment on tear production in dogs, J. Am. Vet. Med. Assoc. 205 (1994) 1286-1289.
37. K. Tsubota, New approaches to dry-eye therapy, Int. Ophthalmol. 34 (1994) 115-128.
38. D.I. Bounous, K.P. Carmichael, R.L. Kaswan, Effects of ophthalmic cyclosporine on lacrimal gland pathology and function in dogs with keratoconjunctivitis sicca, Vet. Compar. Ophthalmol. 5 (1995) 5-12.
39. R.J. Fullard, R.I. Kaswan, D.A. Keller, Comparison of vehicles used in topical cyclosporine treatment of canine KCS, Invest. Ophthalmol. Vis. Sci. 36 (1994) S994.
40. R.J. Fullard, R.M. Kaswan, D.I. Bounous, S.G. Hirsh, Tear protein profiles vs. clinical characteristics of untreated and cyclosporine-treated canine KCS, J. Am. Optom. Assoc. 66 (1995) 397-404.
41. R.L. Kaswan, M.A. Salisbury, D.A. Ward, Spontaneous canine keratoconjunctivitis sicca. A useful model for human keratoconjunctivitis sicca: treatment with cyclosporine eye drops, Arch. Ophthalmol. 107 (1989) 1210-1216.
42. R.L. Kaswan, M.A. Salisbury, A new perspective on canine keratoconjunctivitis sicca. Treatment with ophthalmic cyclosporine, Vet. Clin. North Am. Small Anim. Pract. 20 (1990) 583-613.
43. R.V. Morgan, K.L. Abrams, Topical administration of cyclosporine for treatment of keratoconjunctivitis sicca in dogs, J. Am. Vet. Med. Assoc. 199 (1991) 1043-1046.
44. D.K. Olivero, M.G. Davidson, R.V. English, M.P. Nasisse, V.E. Jamieson, T.M. Gerig, Clinical evaluation of 1% cyclosporine for topical treatment of keratoconjunctivitis sicca in dogs, J. Am. Vet. Med. Assoc. 199 (1991) 1039-1042.
45. M.R. Salisbury, R.L. Kaswan, D.A. Ward, Topical application of cyclosporine in the management of keratoconjunctivitis sicca in dogs, J. Am. Anim. Hosp. Assoc. 26 (1990) 269-274.
46. M.R. Salisbury, R.L. Kaswan, J. Brown, Microorganisms isolated from the corneal surface before and during topical cyclosporine treatment in dogs with keratoconjunctivitis sicca, Am. J. Vet. Res. 56 (1995) 880-884.
47. R.A. Read, Treatment of canine nictitans plasmacytic conjunctivitis with 0.2 per cent cyclosporin ointment, J. Small. Anim. Pract. 36 (1995) 50-56.
48. R.A. Read, K.C. Barnett, J. Sansom, Cyclosporin-responsive keratoconjunctivitis in the cat and horse, Vet. Rec. 137 (1995) 170-181.
49. J. Sansom, K.C. Barnett, W. Neumann, A. Schulte Neumann, B. Clerc, J.P. Jegou, V. de-Haas, A. Weingarten, Treatment of keratoconjunctivitis sicca in dogs with cyclosporine ophthalmic ointment: a European clinical field trial, Vet. Rec. 137 (1995) 504-507.
50. P.A. Jackson, R.L. Kaswan, R.E. Meredith, P.M. Barrett, Chronic superficial keratitis in dogs: A placebo controlled trial of topical cyclosporine treatment, Prog. Vet. Comp. Ophthalmol. 1 (1991) 269-275.
51. S.M. Drance, M.E. Van Buskirk, A.H. Neufeld, (Eds.) Pharmacology in Glaucoma. Williams and Wilkins, Baltimore, 1992.
52. K.N. Gelatt, Glaucoma in animals, Anim. Eye Res. 12 (1993) 1-14.
53. B.P. Wilcock, R.L. Peiffer Jr., M.G. Davidson, The causes of glaucoma in cats, Vet. Pathol. 27 (1990) 35-40.
54. D.E. Brooks, Glaucoma in the dog and cat, Vet. Clin. North Am. Small Anim. Pract. 20 (1990) 775-797.
55. R.M. Gwin, K.N. Gelatt, G.G. Gum, R.L. Peiffer Jr., L.W Williams, The effect of topical pilocarpine on intraocular pressure and pupil size in the normotensive and glaucomatous Beagle, Invest. Ophthalmol. Vis. Sci. 16 (1977) 1143-1148.
56. M. Carrier, G.G. Gum, Effects of topical 4% pilocarpine gel on normotensive and glaucomatous canine eye, Am. J. Vet. Res. 50 (1989) 239-244.
57. K.N. Gelatt, G.G. Gum, E.D. Wolf, M.M. White, Dose-response of topical carbamylcholine chloride (carbachol) in the normotensive and glaucomatous Beagle, Am. J. Vet. Res. 45 (1984) 547-554.
58. G.G. Gum, K.N. Gelatt, R. Jones, The effect of topical demecarium bromide and echothiophate iodine on intraocular pressure and pupil size in normotensive Beagles and Beagles with inherited glaucoma, Am. J. Res. 54 (1993) 287-293.
59. G.G. Gum, K.J. Metzger, K.J. Gelatt, R.L. Gilley, K.N. Gelatt, The tonographic effect of pilocarpine and pilocarpine-epinephrine in normal Beagles and Beagles with inherited glaucoma, J. Small Anim. Pract. 34 (1993) 112-116.
60. R.M. Gwin, K.N. Gelatt, G.G. Gum, R.L. Peiffer Jr., Effects of topical 1%-epinephrine and dipivalyl epinephrine on intraocular pressure and pupil size in the normotensive and glaucomatous Beagle, Am. J. Vet. Res. 39 (1978) 83-86.
61. K.N. Gelatt, G.G. Gum, D.E. Brooks, E.D. Wolf, N.M. Bromberg, Dose response of topical pilocarpine-epinephrine combinations in the normotensive and glaucomatous Beagle, Am. J. Vet. Res. 44 (1983) 2018-2027.
62. A.I. Mandel, F. Stentz, A.E. Kitabchi, Dipivalyl epinephrine: a new pro-drug in the treatment of glaucoma, Ophthalmology 85 (1978) 268-275.
63. B.K. Colasabti, R.R. Trotter, Effects of selective beta-1 and beta-2 adrenocepter agonists and antagonists on intraocular pressure in the cat, Invest. Ophthalmol. Vis. Sci. 20 (1981) 69-76.
64. J.P. Picket, L.J. Majors, Short term and long term effects of topical timolol maleate and betaxolol on intraocular pressure, heart rate, and blood pressure in normal dogs. 20th Transactions Am. Coll. Vet. Ophthalmol., 1989, p. 1.
65. G.G. Gum, R.D. Larocca, K.N. Gelatt, J.P. Mead, J.K. Gelatt, The effects of topical timolol maleate on intraocular pressure and pupil size in normal Beagles and Beagles with inherited glaucoma, Prog. Vet. Comp. Ophthalmol. 1 (1991) 141-149.
66. D.A. Wilkie, C.A. Latimer, Effects of topical administration of timolol maleate on intraocular pressure and pupil size in cats, Am. J. Vet. Res. 52 (1991) 436-440.
67. M.L. Sears, Autonomic nervous system: Adrenergic agonists, in: Handbook of Experimental Pharmacology. Pharmacology of the Eye. Springer, Verlag, Berlin. Vol. 69, 1984, pp. 193-248.
68. K.N. Gelatt, R.D. Larocca, J.K. Gelatt, D.T. Strubbe, E.O. MacKay, Evaluation of multiples doses of 4% and 6% timolol, and timolol combined with 2% pilocarpine in normotensive and glaucomatous Beagles, Am. J. Vet. Res. 56 (1995) 1325-1331.
69. P.E. Miller, S.L. Rhaesa, Effects of topical administration of 0.5% apraclonidine on intraocular pressure, pupil size, and heart rate in clinically normal cats, Am. J. Vet. Res. 57 (1996) 83-86.
70. 2α increases uveoscleral outflow in cynomologus monkey, Exp. Eye Res. 49 (1989) 389-402.
71. A. Aim, J. Villumsen, P Tornquist, A. Mandahl, J. Airaksinen, A. Tuulonen, A. Marsk, B. Resul, J. Stjernschantz, Intraocular pressure-reducing effect of PhXA41 in patients with increased eye pressure. A one-month study, Ophthalmology 100 (1993) 1312-1316.
72. 2α isopropyl ester on intraocular pressure in normotensive and glaucomatous canine eyes, J. Ocular Pharm. 7 (1991) 107-116.
73. P Peinado-Ramon, M. Salvador, M.P Villegas-Perez, M. Vidal-Sanz, Effects of axotomy and intraocular administration of NT-4, NT-3, and brain-derived neurotrophic factor on the survival of adult rat retinal ganglion cells. A quantitative in vivo study, Invest. Ophthalmol. Vis. Sci. 37 (1996) 489-500.
74. S. Harino, C.E. Riva, B.L. Petrig, Intravenous nicardipine in cats increases optic nerve head but not retinal blood flow, Invest. Ophthalmol. Vis. Sci. 33 (1992) 2885-2890.
75. D.L. Hatchell, J.L. Ubels, T. Stekiel, M.C. Hatchell, Corneal epithelial wound healing in normal and diabetic rabbits treated with tretinoin, Arch. Ophthalmol. 103 (1985) 98-100.
76. J.L. Ubels, H.F. Edelhauser, K.M. Foley, The efficacy of retinoic acid ointment for treatment of xerophthalmia and corneal epithelial wounds, Curr. Eye Res. 10 (1985) 1049.
77. G. Petroutsos, J. Courty, R. Guimaraes, Y. Pouliquen, D. Barritault, J. Plouet, Y. Courtois, Comparison of the effects of EGF, pFGF and EDGF on corneal epithelium wound healing, Curr. Eye Res. 3 (1984) 593-598.
78. K. Watanabe, S. Nakagawa, T. Nishida, Stimulatory effects of fibronectin and EGF on migration of corneal epithelial cells, Invest. Ophthalmol. Vis. Sci. 28 (1987) 205-211.
79. D. Fredj-Reygrobellet, J. Plovet, T. Delayre, C. Baudouin, F. Bourret, P. Lapalus, Effects of aFGF and bFGF on wound healing in rabbit corneas, Curr. Eye Res. 6 (1987) 1205-1209.
80. R.B. Miller, W.H. Fales, Infectious bovine keratoconjunctivitis: an update, Vet. Clin. North Am. Large Anim. Pract. 6 (1984) 597-608.
81. D.H. Slatter, A national survey of the clinical features, treatment, and importance of infectious bovine keratoconjunctivitis, Aust. Vet. J. 59 (1982) 69.
82. L.W. George, Antibiotic treatment of infectious bovine keratoconjunctivitis, Cornell Vet. 80 (1990) 229-235.
83. P.I. Punch, N.D. Costa, M.E. Edwards, G.E. Wilcox, The release of insoluble antibiotics from collagen ocular inserts in vitro and their insertion into the conjunctival sac of cattle, J. Vet. Pharmacol. Ther. 10 (1987) 37-42.
84. D.H. Slatter, N.D. Costa, M.E. Edwards, Ocular inserts for application of drugs to bovine eyes - in vivo and in vitro studies on the release of gentamicin from collagen inserts, Aust. Vet. J. 59 (1982) 4-6.
85. S.W. Kim, Y.H. Bae, T. Okano, Hydrogels: swelling, drug loading, and release, Pharm. Res. 9 (1992) 283-290.
86. P. Buri, F. Gurtler, Les formes opthtalmiques à action prolongée. In: M. van Ooteghem (Ed.), Préparations Ophtalmiques, Lavoisier, Paris, 1995, pp. 127-215.
87. A. Rozier, C. Mazuel, J. Grove, B. Plazonnet, Gelrite: A novel, ion-activated, in situ gelling polymer for ophthalmic vehicles. Effect on bioavailability of timolol, Int. J. Pharm. 57 (1989) 163-168.
88. C. Mazuel, M.C. Friteyre, Ophthalmological composition of the type which undergoes liquid-gel phase transition, US Patent 4861 760, 1989.
89. J.L. Greaves, C.G. Wilson, A. Rozier, B. Plazonnet, Scintigraphic assessment of an ophthalmic gelling vehicle in man and rabbit, Curr. Eye Res. 9 (1990) 415-420.
90. J.C. Gilbert, C. Washington, M.C. Davies, J. Hadgraft, The behaviour of Pluronic F127 in aqueous solution studied using fluorescent probes, Int. J. Pharm. 40 (1987) 93-99.
91. T. Boye, Développement de nouvelles formes ophtalmiques à libération prolongée et évaluation de la durée de leur activité pharmacologique, Ph.D. thesis, University of Geneva, 1986.
92. R. Gurny, H. Ibrahim, T. Boye, Latices and thermosensitive gels as sustained delivery systems to the eye, in: M.F. Saettone, M. Bucci, P. Speiser (Eds.), Ophthalmic Durg Delivery. Biopharmaceutical, Technological and Clinical aspects, Liviana Press, Padova, 1987, pp. 27-36.
93. R. Gurny, H. Ibrahim, A. Aebi, P. Buri, C.G. Wilson, N. Washington, P. Edman, O. Camber, Design and evaluation of controlled release systems for the eye, J. Control. Rel. 6 (1987) 367-373.
94. H. Ibrahim Khalil, Concept et évaluation de systèmes polymèriques dispersés (pseudo-latex) à usage ophtalmique, Ph.D. Thesis, University of Geneva, 1989.
95. S. Kumar, B.O. Haglund, K.J. Himmelstein, In situ-forming gels for ophthalmic drug delivery, J. Ocular. Pharmacol. 10 (1994) 47-56.
96. M. van Ooteghem, Formulations of ophthalmic solutions and suspensions. Problems and advantages, in: P. Edman (Ed.), Biopharmaceutics of Ocular Drug Delivery, CRC Press, Boca Raton, FL, 1993, pp. 27-42.
97. M. Zignani, C. Tabatabay, R. Gurny, Topical semi-solid drug delivery: kinetics and tolerance of ophthalmic hydrogels, Adv. Drug Del. Rev. 16 (1995) 51-60.
98. M.F. Saettone, P. Chetoni, M.T. Torracca, S. Burgalassi, B. Giannaccini, Evaluation of muco-adhesive properties and in vivo activity of ophthalmic vehicles based on hyaluronic acid, Int. J. Pharm. 51 (1989) 203-212.
99. D.A. Benedetto, D.O. Shah, H.E. Kaufmann, The instilled fluid dynamics and surface chemistry of polymers in the preocular tear film, Invest. Ophthalmol. Vis. Sci. 14 (1975) 887-902.
100. A.F. Thermes, Interactions de polymères avec les tissus oculaires. Ph.D. thesis, University of Geneva, 1991.
101. H. Park, J.R. Robinson, Mechanisms of mucoadhesion of poly(acrylic acid) hydrogels, Pharm. Res. 4 (1987) 457-464.
102. J.R. Robinson, G.M. Mlynek, Bioadhesive and phase-change polymers for ocular drug delivery, Adv. Drug Del. Rev. 16 (1995) 45-50.
103. S.F. Bernatchez, C. Tabatabay, R. Gurny, Sodium hyaluronate 0.25% used as a vehicle increases the bioavailability of topically administered gentamicin, Graefe's Arch. Clin. Exp. Ophthalmol. 231 (1993) 157-171.
104. C. Tabatabay, Instillation d'acide hyaluronique à 0,1% lors de kératite sèche sévère, J. Fr. Ophtalmol. 8 (1985) 513.
105. P.D. Amin, C.P. Bhogte, M.A. Deshpande, Studies on gel tears, Drug Dev. Ind. Pharm. 22 (1996) 735-739.
106. A. Ludwig, M. van Ooteghem, Influence of viscolysers on the residence of ophthalmic solutions evaluated by slit lamp fluorophotometry, S.T.P. Pharma Sciences 2 (1992) 81-87.
107. A. Ludwig, N.J. van Haeringen, V.M.W. Bodelier, M. van Ooteghem, Relationship between precorneal retention of viscous eye drops and tear fluid composition, Int. Ophthalmol. 16 (1992) 23-26.
108. A. Ludwig, M. van Ooteghem, Influence of the viscosity and the surface tension of ophthalmic vehicles on the retention of a tracer in the precorneal area of human eyes, Drug Dev. Ind. Pharm. 14 (1988) 2267-2284.
109. N. Krishna, F. Brow, Polyvinyl alcohol as an ophthalmic vehicle, Am. J. Ophthalmol. 57 (1964) 99-106.
110. A. Ludwig, M. van Ooteghem, Evaluation of sodium hyaluronate as viscous vehicle for eye drops, J. Pharm. Belg. 44 (1989) 391-397.
111. [Ill] G.R. Snibson, J.L. Greaves, N.D.W. Soper, J.I. Prydal, C.G. Wilson, A.J. Bron, Precorneal residence times of sodium hyaluronate solutions studied by quantitative gamma scintigraphy, Eye 5 (1990) 594-602.
112. E. Verschueren, L. Van Santvliet, A. Ludwig, Evaluation of various carrageenans as ophthalmic viscolysers, S.T.P. Pharma Sciences 6 (1996) 203-210.
113. F.P. Gunning, E.L. Greve, A.M. Bron, J.M. Bosc, J.G. Royer, J.L. George, P. Lesure, D. Sirbat, Two typical carbonic anhydrase inhibitors sezolamide and drozolamide in gelrite vehicle: a multiple-dose efficacy study, Graefe's Arch. Clin. Exp. Ophthalmol. 231 (1993) 384-388.
114. Y.D. Sanzgiri, S. Mashi, V. Crescenzi, L. Callegaro, E.M. Topp, V.J. Stella, Gellan-based systems for ophthalmic sustained delivery of methylprednisolone, J. Control. Rel. 26 (1993) 195-201.
115. T.P. Werblin, S.D. Rheinstrom, H.E. Kaufman, The use of slow-release artificial tears in the long-term management of keratitis sicca, Ophthalmology 88 (1981) 78-81.
116. V.K.W. Wong, S. Shapourifar-Tehrani, S. Kitada, P.H. Choo, D.A. Lee, Inhibition of rabbit ocular fibroblast proliferation by 5-fluorouracil and cytosine arabinoside, J. Ocular. Pharmacol. 7 (1991) 27-39.
117. M.S. Blumenkranz, A. Claflin, A.S. Hajek, Selection of therapeutic agents for intraocular proliferative disease, Arch. Ophthalmol. 102 (1984) 598-604.
118. P.T. Khaw, J.W. Doyle, M.B. Sherwood, M.F. Smith, S. McGorray, Effects of intraoperative 5-fluorouracil or mitomycin C on glaucoma filtration surgery in the rabbit, Ophthalmology 100 (1993) 367-372.
119. F. Gurtler, R. Gurny, Patent literature review of ophthalmic inserts, Drug Dev. Ind. Pharm. 21 (1995) 1-18.
120. S.E. Bloomfield, T. Miyata, M.W. Dunn, N. Bueser, K.H. Stenzel, A.L. Rubin, Soluble gentamicin ophthalmic inserts as a drug delivery system, Arch. Ophthalmol. 96 (1978) 885-887.
121. K.K. Assil, S.R. Zarnegar, B.D. Fouraker, D.J. Schanzlin, Efficacy of tobramycin-soaked collagen shields vs tobramycin eyedrop loading dose for sustained treatment of experimental Pseudomonas aeruginosa induced keratitis in rabbits, Am. J. Ophthalmol. 113 (1992) 418.
122. J.K. Milani, I. Verbukh, U. Pleyer, H. Sumner, S.A. Adamu, H.P. Halabi, H.J. Chou, D.A. Lee, B.J. Mondino, Collagen shields impregnated with gentamicin-dexamethasone as potential drug delivery device, Am. J. Ophthalmol. 116 (1993) 622-627.
123. M.F. Saettone, P. Chetoni, M.T. Torraca, B. Giannaccini, L. Naber, U. Conte, M.E. Sangalli, A. Gazzaniga, Application of the compression technique to the manufacture of pilocarpine inserts, Acta Pharm. Technol. 36(1) (1990) 15-19.
124. M.F. Saettone, M.T. Torraca, A. Pagano, B. Giannaccini, L. Rodriguez, M. Cini, Controlled release of pilocarpine from coated polymeric ophthalmic inserts prepared by extrusion, Int. J. Pharm. 86 (1992) 159.
125. S.P. Loucas, M. Heskel, M. Haddad, Solid state ophthalmic dosage system-II Use of polyuronic acid in effecting prolonged delivery of pilocarpine in the eye, Metab. Ophthalmol. 1 (1976) 27.
126. A. Urtti, L. Salminen, O. Miinalainen, Systemic absorption of ocular pilocarpine is modified by polymer matrices, Int. J. Pharm. 23 (1985) 147.
127. Y. Yamamoto, Y. Kaga, T. Yoshikawa, A. Moribe, Ultraviolet-hardenable adhesive, US Patent. 5145 884, 1992.
128. F. Gurtler, V. Kaltsatos, B. Boisramé, R. Gurny, Long-acting soluble bioadhesive ophthalmic drug insert (BODI) containing gentamicin for veterinary use: optimization and clinical investigation, J. Control. Rel. 33 (1995) 231-236.
129. M.A. Attia, M.A. Kassem, S.M. Safwat, In vivo performance of 3-H-dexamethasone ophthalmic film delivery system in the rabbit eye, Int. J. Pharm. 47 (1988) 21.
130. V.H.L. Lee, S. Yong Li, H. Sasaki, M.F. Saettone, P. Chetoni, Influence of drug release rate on systemic timolol absorption from polymeric ocular inserts in the pigmented rabbit, J. Ocular Pharmacol. 10 (1994) 421-429.
131. V.H.L. Lee, S. Li, M.F. Saettone, P. Chetoni, H. Bundgaard, Systemic and ocular absorption of timolol prodrugs from erodible inserts, Proc. Int. Symp. Control. Rel. Bioact. Mater. 18 (1991) 291.
132. G.M. Grass, J. Cobby, M.C. Makoid, Ocular delivery of pilocarpine from erodible matrices, J. Pharm. Sci. 73 (1984) 618-621.
133. P.I. Punch, D.H. Slatter, N.D. Costa, M.E. Edwards, Investigation of gelatin as a possible biodegradable matrix for sustained delivery of gentamicin to the bovine eye, J. Vet. Pharmacol. Therap. 8 (1985) 335-338.
134. D. Pavan-Langston, R.H.S. Langsten, P.A. Geary, Idox-uridine ocular insert therapy: use in treatment of experimental herpes simplex keratitis, Arch. Ophthalmol. 93 (1975) 1349.
135. L. Sendelbeck, D. Moore, J. Urqhart, Comparative distribution of pilocarpine in ocular tissues of the rabbit during administration by eyedrop or by membrane-controlled delivery systems, Am. J. Ophthalmol. 80 (1975) 274-283.
136. M.F. Saettone, D. Monti, M.T. Torracca, P. Chetoni, B. Giannaccini, Muco-adhesive liquid ophthalmic vehicles. Evaluation of macromolecular ionic complexes of pilocarpine, Drug Dev. Ind. Pharm. 15 (1989) 2475-2489.
137. N.M. Davies, S.J. Farr, J. Hadgraft, I.W. Kellaway, Evaluation of mucoadhesive polymers in ocular drug delivery. I: Viscous solutions, Pharm. Res. 8 (1991) 1039-1043.
138. R.D. Schoenwald, R.L. Ward, L.M. DeSantis, R.E. Roehrs, Influence of high-viscosity vehicles on miotic effect of pilocarpine, J. Pharm. Sci. 67 (1978) 1280-1283.
139. G. Pergande, S. Keipert, A. Klatt, Antiglaukomatosisahaltige Ophthalmika mit prolongierter Wirkung auf Basis makromolekularer Hilsstoffe Teil 2: In vivo-Untersuchungen, Pharmazie 45 (1990) 587-591.
140. S.G. Deshpande, S. Shirokolar, Sustained release ophthalmic formulations of pilocarpine, J. Pharm. Pharmacol. 41 (1989) 197-200.
141. S.S. Chrai, J.R. Robinson, Ocular evaluation of methylcellulose vehicle in albino rabbits, J. Pharm. Sci. 63 (1974) 1218-1223.
142. M.F. Saettone, B. Giannaccini, A. Teneggi, P. Savigni, N. Tellini, Vehicle effects on ophthalmic bioavailability: the influence of different polymers on the activity of pilocarpine in rabbit and man, J. Pharm. Pharmacol. 34 (1982) 464-466.
143. S.P. Vyas, C.P. Ramchandraiah, C.P. Jain, S.K. Jain, Polyeric pseudolatices bearing pilocarpine for controlled ocular delivery, J. Microencapsul. 9 (1992) 347-355.
144. G.M. Meseguer, Etude comparative de formes ophtalmiques gélifiées chez l'homme et l'animal par scintigraphie gamma et mesure de la réponse myotique. Ph.D. thesis, University of Geneva, 1993.
145. U. Ticho, M. Blumenthal, S. Zonis, A. Gal, I. Blank, Z.W. Mazor, Piloplex, a new long-acting pilocarpine polymer salt. A: Long-term study, Br. J. Ophthalmol. 63 (1979) 45-47.
146. Z. Mazor, U. Ticho, U. Rehany, L. Rose, Piloplex, a new long-acting pilocarpine polymer salt. B: Comparative study of the visual effects of pilocarpine and Piloplex eye drops, Br. J. Ophthalmol. 63 (1979) 48-51.
147. P. Jarho, K. Järvinen, A. Urtti, V.J. Stella, T. Järvinen, Modified beta-cyclodextrin (SB7-beta-CyD) with viscous vehicle improves the ocular delivery and tolerability of pilocarpine prodrug in rabbits, J. Pharm. Pharmacol. 48 (1996) 263-269.
148. J.L. Greaves, O. Olejnik, C.G. Wilson, Polymers and the precorneal tear film, S.T.P. Pharma Sci. 2 (1992) 13-33.
149. R. Gurny, H. Ibrahim, P. Buri, The development and use of in situ formed gels, triggered by pH, in: P. Edman (Ed.), Biopharmaceutics of Ocular Drug Delivery, CRC Press, Boca Raton, FL, 1993, pp. 81-90.
150. S.C. Miller, M.D. Donovan, Effect of poloxamer 407 gel on the miotic activity of pilocarpine nitrate on rabbits, Int. J. Pharm. 12 (1982) 147-152.
151. L. Salminen, A. Urtti, H. Kujari, M. Juslin, Prolonged pulse-entry of pilocarpine with a soluble drug insert, Greafe's Arch. Clin. Exp. Ophthalmol. 221 (1983) 96.
152. M.F. Saettone, P. Chetoni, M.T. Torraca, S. Burgalassi, B. Giannaccini, Evaluation of muco-adhesive properties and in vivo activity of ophthalmic vehicles based on hyaluronic acid, Int. J. Pharm. 51 (1989) 203.
153. H. Mayer, N. von der Ohe, Efficacy of a novel hydrogel formulation in human volunteers, Ophthalmologica 210 (1996) 101-103.
154. K. Järvinen, A. Urtti, Cardiac effects of different eyedrop preparations of timolol in rabbits, Curr. Eye Res. 11 (1992) 469-473.
155. K. Kyyrönen, A. Urtti, Improved ocular systemic absorption ratio of timolol by viscous vehicle and phenylephrine, Invest. Ophthalmol. Vis. Sci. 31 (1990) 1827-1833.
156. K. Järvinen, E. Vartiainen, A. Urtti, Optimizing the systemic and ocular absorption of timolol from eye-drops, S.T.P. Pharma Sci. 2 (1992) 105-110.
157. K. Dickstein, T. Aarsland, Comparison of the effects of aqueous and gellan ophthalmic timolol on peak exercise performance in middle-aged men, Am. J. Ophthalmol. 121 (1996) 367-371.
158. H. Sasaki, C. Tei, K. Nishida, J. Nakamura, Drug release of an ophthalmic insert of a beta-blocker as an ocular drug delivery system, J. Control. Rel. 27 (1993) 127.
159. R. Jani, O. Can, Y. Ali, R. Rodstrom, S. Hancock, Ion-exchange resins for ophthalmic delivery, J. Ocular. Pharmacol. 10 (1994) 57-67.
160. M.F. Saettone, B. Giannaccini, S. Ravecca, F. La Marca, G. Tola, Polymer effects on ocular bioavailability the influence of different liquid vehicles on the mydriatic response of tropicamide in humans and rabbits, Int. J. Pharm. 20 (1984) 187-202.
161. M.F. Saettone, B. Giannaccini, F. Barattini, N. Tellini, The validity of rabbits for investigations on ophthalmic vehicles: a comparison of four different vehicles containing tropicamide in humans and rabbits, Pharm. Acta Helv. 2 (1982) 3-11.
162. H.W. Larsen, Fucithalmic pharmacokinetic in healthy volunteers, Study report, 1980.
163. J. Hvidberg, Fusidic acid in acute conjunctivitis, Acta Ophthalmol. 65 (1987) 43-47.
164. C.-M. Lehr, Y.-H. Lee, V.H.L. Lee, Improved ocular penetration of gentamicin by mucoadhesive polymer polycarbophil in the pigmented rabbit, Invest. Ophthalmol. Vis. Sci. 35 (1994) 2809-2814.
165. M. Fonseca, A. Cabanes, M.A. Alsina, F. Reig, Design of a new formulation for sustained release of gentamicin: a carbopol hydrogel, Int. J. Pharm. 133 (1996) 265-268.
166. S. Hosaka, H. Ozawa, H. Tanzawa, In vivo evaluation of ocular inserts of hydrogel impregnated with antibiotics for trachoma therapy, Biomaterials 4 (1983) 243.
167. H. Ozawa, S. Hosaka, T. Kunitomo, H. Tanzawa, Ocular inserts for controlled release of antibiotics, Biomaterials 4 (1983) 170-174.
168. L. Romanelli, P. Valeri, L.A. Morrone, G. Pimpinella, G. Graziani, B. Tita, Ocular absorption and distribution of benzadac after topical administration to rabbits with different vehicles, Life Sci. 13 (1994) 877-885.
169. R.D. Schoenwald, J.J. Boltralik, A bioavailability comparison in rabbits of two steroids formulated as high viscosity gels and reference aqueous preparations, Invest. Ophthalmol. Vis. Sci. 18 (1979) 61-66.
170. V.K. Tamara, M.A. Crider, Prodrugs: A chemical approach to ocular delivery, in: I.K. Reddy (Ed.), Ocular Therapeutics and Drug Delivery: A Multi-Disciplinary Approach, Technomic Publishing, Lancaster, 1996, pp. 285-334.
171. V.H.L. Lee, Minimizing the systemic absorption of topically applied ophthalmic drugs in rabbits, STP Pharma. 2 (1992) 5.
172. V.H.L. Lee, V.H.K. Li, Prodrugs for improved ocular drug delivery, Adv. Drug Del. Rev. 3 (1989) 1-38.
173. L. Apt, A. Henrick, L.M. Silverman, Patient compliance with the use of topical ophthalmic corticosteroid suspensions, Am. J. Ophthalmol. 87 (1979) 210-214.
174. H.M. Leibowitz, R.L. Kimbrough, A. Kupferman, R.H. Stewart, Evaluation of dexamethasone acetate as a topical ophthalmic formulation, Am. J. Ophthalmol. 86 (1978) 418-423.
175. H.M. Leibowitz, A. Kupferman, Anti-inflammatory effectiveness in the cornea of topically administered prednisolone, Invest. Ophthalmol. Vis. Sci. 13 (1974) 757-763.
176. A. Kupferman, A.R. Berrospi, H.M. Leibowitz, Fluorometholone acetate: a new ophthalmic derivative of fluorometholone acetate, Arch. Ophthalmol. 100 (1982) 640-641.
177. W.V. Cox, A. Kupferman, H.M. Leibowitz, Topically applied steroids in corneal disease I. The role of inflammation in stromal absorption of dexamethasone, Arch. Ophthalmol. 88 (1972) 308-313.
178. S.C. Chang, H. Bundgaard, A. Buur, V.H.L. Lee, Improved corneal penetration of timolol by prodrugs as a means to reduce systemic drug load, Invest. Ophthalmol. Vis. Sci. 28 (1987) 487-491.
179. S.C. Chang, H. Bundgaard, A. Buur, V.H.L. Lee, Low dose O-butyryl timolol improves the therapeutic index of timolol in the pigmented rabbit, Invest. Ophthalmol. Vis. Sci. 29 (1988) 626-629.
180. H. Bundgaard, E. Falch, C. Larsen, T.J. Mikkelson, Pilocarpine prodrugs I. Synthesis, Physicochemical properties and kinetics of lactonization of pilocarpic acid esters, J. Pharm. Sci. 75 (1986) 36-43.
181. H. Bundgaard, E. Falch, C. Larsen, G.L. Mosher, T.J. Mikkelson, Pilocarpine prodrugs II. Synthesis, stability, bioconversion, and physicochemical properties of sequentially labile pilocarpine acid diesters, J. Pharm. Sci. 75 (1986) 775-783.
182. V.H.L. Lee, H. Bundgaard, Improved ocular delivery with prodrugs, in: K.B. Sloan (Ed.), Prodrugs: Topical and Ocular Drug Delivery, Marcel Dekker, New York, 1992, pp. 221-297.
183. D.A. McCure, in: T. Higuchi, V. Stella (Eds.), Prodrugs as Novel Drug Delivery Systems, American Chemical Society, Washington, DC, 1975, pp. 224.
184. S.-S. Yuan, N. Bodor, Synthesis and activity of (R)-(-)-m-trimethylacetoxy-α-[(methylamino)methyl]benzyl alcohol hydrochloride: A prodrug form of (R)-(-)-phenylephrine, J. Pharm. Sci. 65 (1976) 929-931.
185. D.S. Chien, R.D. Schoenwald, Improving the ocular absorption of phenylephrine, Biopharm. Drug Disposit. 7 (1986) 453-462.
186. D.S. Chien, R.D. Schoenwald, Ocular pharmacokinetics and pharmacodynamics of phenylephrine and phenylephrine oxazolidine in rabbit eyes, Pharm. Res. 7 (1990) 476-483.
187. R.D. Schoenwald, J.C. Folk, V. Kumar, J.G. Piper, In vivo comparison of phenylephrine and phenylephrine oxazolidine instilled in the monkey eye, J. Ocular Pharmacol. 3 (1987) 333-340.
188. N. Bodor, J.J. Kaminski, R.G. Roller, Improved delivery through biological membranes VI. Potent sympathomimetic adrenalone derivatives, Int. J. Pharm. 1 (1978) 189-196.
189. N. Bodor, G. Visor, Formation of adrenaline in the irisciliary body from adrenalone diesters, Exp. Eye Res. 38 (1984) 621-626.
190. N. Bodor, G. Visor, Improved delivery through bioogical membranes. XVII. A site-specific chemical delivery system as a short-acting mydriatic agent, Pharm. Res. 4 (1984) 168-173.
191. T.L. Phipps, D.E. Potter, J.M. Rowland, Effects of ibuterol, a beta-2
192. E. Duzman, C.-C. Chen, J. Anderson, M. Blumenthal, H. Twizer, Diacetyl derivative of nadolol: Ocular pharmacology and short-term ocular hypotensive effect in glaucomatous eyes, Arch. Ophthalmol. 100 (1982) 1916-1919.
193. H. Bundgaard, A. Buur, S.C. Chang, V.H.L. Lee, Prodrugs of timolol for improved ocular delivery: synthesis, hydrolysis kinetics and lipophilicity of various timolol esters, Int. J. Pharm. 33 (1986) 15-26.
194. H. Bundgaard, A. Buur, S.C. Chang, V.H.L. Lee, Timolol prodrugs: synthesis, stability and lipophilicity of various alkyl, cycloalkyl and aromatic esters of timolol, Int. J. Pharm. 46 (1988) 77-88.
195. H. Sasaki, D.S. Chien, K. Lew, H. Bundgaard, V.H.L. Lee, Timolol prodrugs: enhanced potency and duration of ocular beta adrenergic blockade following topical solution instillation in the pigmented rabbit, Invest. Ophthalmol. Vis. Sci. (suppl.) (1988) 83.
196. S.C. Chang, D.S. Chien, H. Bundgaard, V.H.L. Lee, Relative effectiveness of prodrug and viscous solution approaches in maximizing the ratio of ocular to systemic absorption of topically applied timolol, Exp. Eye Res. 46 (1988) 59-69.
197. D.S. Chien, H. Bundgaard, A. Buur, V.H.L. Lee, Influence of corneal epithelial integrity on the penetration of timolol prodrugs, J. Ocular Pharmacol. 4 (1988) 137-146.
198. J. Alexander, R. Cargill, R. Michelson, H. Schwam, (Acycloxy)alkyl carbamates as novel bioreversible prodrugs for amines: increased permeation through biological membranes, J. Med. Chem. 31 (1988) 318-322.
199. N. Bodor, A. ElKoussi, M. Kano, T. Nakamura, Improved delivery through biological membranes. 26. design, synthesis, and pharmaceutical activity of a novel chemical delivery system for b adrenergic blocking agents, J. Med. Chem. 31 (1988) 100-106.
200. A.A. El-Koussi, N. Bodor, Formation of propranolol in the iris- ciliary body from its propranolol ketoxime precursor - a potential antiglaucoma drug, Int. J. Pharm. 53 (1989) 189-194.
201. N. Bodor, L. Prokai, Site- and stereospecific ocular drug delivery by sequential enzymatic bioactivation, Pharm. Res. 7 (1990) 723-725.
202. N. Bodor, in: E.B. Roche (Ed.), Design of Biopharmaceutical Properties Through Prodrugs and Analogs, American Pharmaceutical Association, Washington, DC, 1977, pp. 98.
203. H. Bundgaard, E. Falch, C. Larsen, G.L. Mosher, T.J. Mikkelson, Pilocarpic acid esters as novel sequentially labile prodrugs for improved ocular delivery, J. Med. Chem. 28 (1985) 979-981.
204. L.Z. Bito, Comparison of the ocular hypotensive efficacy of eicosanoids and related compounds, Exp. Eye Res. 38 (1984) 181-194.
205. 2α-1-isopropyl ester, Exp. Eye Res. 44 (1987) 217-226.
206. 2α and its isopropyl ester in vitro, Int. J. Pharm. 37 (1987) 27-32.
207. 2α esters across cornea in vitro, Int. J. Pharm. 29 (1986) 259-266.
208. 2-1-isopropyl ester is the most potent reported hypotensive agent on feline eyes, Exp. Eye Res. 50 (1990) 419-428.
209. P. Maudgal, K. De Clercq, J. Descamps, L. Missotten, Topical treatment of experimental herpes simplex keratouveitis with 2′-O-glycylacyclovir: A water-soluble ester of acyclovir, Arch. Ophthalmol. 102 (1984) 140-142.
210. D. Pavan-Langston, R.D. North, P.A. Geary, A. Kinkel, Intraocular penetration of the soluble antiviral, ara AMP, Arch. Ophthalmol. 94 (1976) 1585-1588.
211. M.M. Narurkar, A.K. Mitra, Prodrugs of 5-iodo-2′-deoxyuridine for enhanced ocular transport, Pharm. Res. 6 (1989) 887-891.
212. M.M. Narurkar, A.K. Mitra, Synthesis, physicochemical properties, and cytotoxicity of a series of 5′-ester prodrugs of 5-iodo-2′-deoxyuridine, Pharm. Res. 5 (1988) 734-737.
213. J.A. Schulman, G.A. Peyman, Intracameral, intravitreal and retinal drug delivery, in: A.K. Mitra (Ed.), Ophthalmic Drug Delivery Systems, Marcel Dekker, New York, 1993, pp. 383-425.
214. J. Stjernschantz, M. Astin, Anatomy and physiology of the eye. Physiological aspects of ocular drug therapy, in: P. Edman (Ed.), Biopharmaceutics of Ocular Drug Delivery, CRC press, Boca Raton, FL, 1993, pp. 1-25.
215. L. Von Sallmann, K. Meyer, J. Di Grandi, Experimental study on penicillin treatment of ectogenous infection of vitreous, Arch. Ophthalmol. 32 (1944) 179-189.
216. I.H. Leopold, Intravitreal penetration of penicillin and penicillin therapy of infections of the vitreous, Arch. Ophthalmol. 33 (1945) 211-216.
217. B.W. Rycroft, Penicillin and the control of deep intra-ocular infection, Br. J. Ophthalmol. 29 (1945) 57-87.
218. J. Schneider, S.S. Frankel, Treatment of later postoperative intraocular infections with intraocular injection of penicillin, Arch. Ophthalmol. 37 (1947) 304.
219. G.A. Peyman, D.R. May, E.S. Ericson, D. Apple, Intraocular injection of gentamicin: Toxic effects and clearance, Arch. Ophthalmol. 92 (1974) 42-47.
220. A.J. Axelrod, G.A. Peyman, D.J. Apple, Toxicity of intravitreal injection of amphotericin B, Am. J. Ophthalmol. 76 (1973) 578-583.
221. R.O. Graham, G.A. Peyman, Intravitreal injection of dexamethasone: Treatment of experimentally induced endophthalmitis, Arch. Ophthalmol. 92 (1974) 149-154.
222. T.O. Bennett, G.A. Peyman, Toxicity of intravitreal aminoglycosides in primates, Can. J. Ophthalmol. 9 (1974) 475-478.
223. G.N. Holland, Y. Sidikaro, A.E. Kreiger, D. Hardy, M.J. Sakamoto, L.M. Frenkel, D.J. Winston, M.S. Gottlieb, Y.J. Bryson, R.E. Champlin, W.G. Ho, R.E. Winters, P.R. Wolfe, J.D. Cherry, Treatment of cytomegalovirus retinopathy with ganciclovir, Ophthalmol. 94 (1987) 815-823.
224. P. Lehoang, B. Girard, M. Robinet, P. Marcel, L. Zazoun, S. Matheron, W Rozenbaum, C. Katlama, I. Morer, J.O. Lernestedt, H. Saraux, Y Pouliquen, M. Gentilini, F. Roussellie, Foscarnet in the treatment of cytomegalovirus retinitis in acquired immune deficiency syndrome, Ophthalmology 96 (1989) 865-874.
225. G.A. Peyman, B. Khoobehi, M. Tawakol, J.A. Schulman, H.A. Mortada, H. Alkan, R. Fiscella, Intravitreal injection of liposome encapsulated ganciclovir in a rabbit model, Retina 7 (1987) 227-229.
226. W.F. Rachal, T.C. Burton, Changing concepts of failures after retinal detachment surgery, Arch. Ophthalmol. 97 (1979) 480-483.
227. M. Blumenkranz, E. Hernandez, A. Ophir, E.W.D. Norton, 5-fluorouracil: new applications in complicated retinal detachment for an established antimetabolite, Ophthalmol. 91 (1984) 122-130.
228. J.J. Araiz, M.F. Refojo, M.H. Arroyo, F.L. Leong, D.M. Albert, F.I. Tolentino, Antiproliferative effect of retinoic acid in intravitreous silicone oil in an animal model of proliferative vitreoretinopathy, Invest. Ophthalmol. Vis. Sci. 34 (1993) 522-530.
229. G.G. Giordano, M.F. Refojo, M.H. Arroyo, Sustained delivery of retinoic acid from microspheres of biodegradable polymer in PVR, Invest. Ophthalmol. Vis. Sci. 34 (1993) 2743-2751.
230. M. Hashizoe, Y. Ogura, H. Kimura, T. Moritera, Y. Honda, M. Kyo, S.H. Hyon, Y. Ikada, Scleral plug of biodegradable polymers for controlled drug release in the vitreous, Arch. Ophthalmology 112 (1994) 1380-1384.
231. T. Moritera, Y. Ogura, Y. Honda, R. Wada, S.H. Hyon, Y. Ikada, Microspheres of biodegradable polymers as a drug-delivery system in the vitreous, Invest. Ophthalmol. Vis. Sci. 32 (1991) 1785-1790.
232. D.P. Hainsworth, J.D. Conklin, J.R. Bierly, D. Ax, P. Ashton, Intravitreal delivery of ciprofloxacin, J. Ocular Pharmacol. 12 (1996) 183-191.
233. K.R. Liu, G.A. Peyman, B. Khoobehi, H. Alkan, R. Fiscella, Intravitreal liposome-encapsulated trifluorothymidine in a rabbit model, Ophthalmology 94 (1987) 1155-1159.
234. R.E. Grossman, D.F. Shou, D.A. Lee, Regional ocular gentamicin levels after transcorneal and transscleral iontophoresis, Invest. Ophthalmol. Vis. Sci. 31 (1990) 909-916.
235. D. Sarraf, D.A. Lee, The role of iontophoresis in ocular drug delivery, J. Ocular Pharmacol. 10 (1994) 69-81.
236. J.M. Hill, R.J. O'Callaghan, J.A. Hobden, Ocular iontophoresis, in: A.K. Mitra (Ed.), Ophthalmic Drug Delivery Systems, Marcel Dekker, New York, 1993, pp. 331-354.
237. J.A. Hobden, D.S. Rootman, R.J. O'Callaghan, J.M. Hill, Iontophoretic application of tobramycin to uninfected and Pseudomonas aeruginosa-infected rabbit corneas, Antimicrob. Agents Chemother. 32 (1988) 978-981.
238. D.S. Rootman, J.A. Hobden, J.A. Jantzen, J.R. Gonzalez, Iontophoresis of tobramycin for the treatment of experimental Pseudomonas keratitis in the rabbit, Arch. Ophthalmol. 106 (1988) 262-265.
239. M. Barza, C. Peckman, J. Baum, Transscleral iontophoresis as an adjunctive treatment for experimental endophthalmitis, Arch. Ophthalmol. 105 (1987) 1418-1420.
240. D.M. Maurice, Micropharmaceutics of the eye, Ocular. Inflam. Ther. 1 (1983) 97-102.
241. L. Hughes, D.M. Maurice, A fresh look at iontophoresis, Arch. Ophthalmol. 102 (1984) 1825-1829.
242. D.S. Rootman, J.R. Gonzalez, J.A. Jantzen, M.J. Fischer, R. Beuerman, J.M. Hill, Pharmacokinetics and safety of transcorneal iontophoresis of tobramycin in the rabbit, Invest. Ophthalmol. Vis. Sci. 29 (1988) 1397-1401.
243. T.B. Choi, D.A. Lee, Transscleral and transcorneal iontophoresis of vancomycin in rabbit eyes, J. Ocular Pharmacol. 4 (1988) 153-164.
244. M. Barza, C. Peckman, J. Baum, Transscleral iontophoresis of cefazolin, tircacillin, and gentamicin in the rabbit, Ophthalmology 93 (1986) 133-139.
245. M. Barza, C. Peckman, J. Baum, Transscleral iontophoresis of gentamicin in monkeys, Invest. Ophthalmol. Vis. Sci. 28 (1987) 1033-1036.
246. P.H. Fishman, W.M. Jay, J.P Rissing, J.M. Hill, R.K. Shockley, Iontophoresis of gentamicin into aphakic rabbit eyes: sustained vitreal levels, Invest. Ophthalmol. Vis. Sci. 25 (1984) 343-345.
247. N.L. Burstein, I.H. Leopold, D.B. Bernacchi, Transscleral iontophoresis of gentamicin, J. Ocular Pharmacol. 1 (1985) 363-368.
248. M.O. Yoshizumi, D. Cohen, I. Verbukh, M. Leinwand, J. Kim, D.A. Lee, Experimental transscleral iontophoresis of ciprofloxacin, J. Ocular Pharmacol. 7 (1991) 163-167.
249. J.M. Hill, N.-H. Park, L.P. Gangarosa, D.S. Hull, C.L. Tuggle, K. Bowman, K. Green, Iontophoresis of vidarabine monophosphate into rabbit eyes, Invest. Ophthalmol. Vis. Sci. 17 (1978) 473-476.
250. D. Sarraf, R.A. Equi, G.N. Holland, M.O. Yoshizumi, D.A. Lee, Transscleral iontophoresis of foscarnet, Am. J. Ophthalmol. 115 (1993) 748-754.
251. M. Kondo, M. Araie, Iontophoresis of 5-fluorouracil into the conjunctiva and sclera, Invest. Ophthalmol. Vis. Sci. 30 (1989) 583-585.
252. R. Grossman, D.A. Lee, transscleral and transcorneal iontophoresis of ketoconazole in the rabbit eye, Ophthalmology 96 (1989) 724-729.
253. T.T. Lam, D.P. Edward, X.-A. Zhu, M.O.M. Tso, Transsleral iontophoresis of dexamethasone, Arch. Ophthalmol. 107 (1989) 1368-1371.